Phase II trial of aminothiadiazole in previously treated and untreated patients with advanced colorectal carcinoma: An Illinois Cancer Council trial

G. Y. Locker, J. Khandekar, S. Krauss, H. Reisel, T. Hoeltgen, J. Wolter, M. Haid, R. Hoffman, R. Blough, C. Johnson

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Eighty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly iv aminothiadiazole (125 mg/m2) plus daily oral allopurinol (300 mg). There were five partial responses. Median survival of all patients on study was 36 weeks from entry (48 weeks for those without prior therapy and 34 weeks for those with previous chemotherapy). Toxicity was generally mild and consisted predominantly of stomatitis. In the dose given, aminothiadiazole has limited activity against metastatic colorectal cancer.

Original languageEnglish (US)
Pages (from-to)649-650
Number of pages2
JournalCancer Treatment Reports
Volume71
Issue number6
StatePublished - 1987

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of aminothiadiazole in previously treated and untreated patients with advanced colorectal carcinoma: An Illinois Cancer Council trial'. Together they form a unique fingerprint.

Cite this